Karyopharm Therapeutics Inc. (KPTI)

Market Cap	257.66M
Revenue (ttm)	148.10M
Net Income (ttm)	-158.02M
Shares Out	114.01M
EPS (ttm)	-1.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,207,783
Open	2.22
Previous Close	2.20
Day's Range	2.15 - 2.30
52-Week Range	2.15 - 6.84
Beta	0.06
Analysts	Buy
Price Target	8.25 (+265.04%)
Earnings Date	May 4, 2023

About KPTI

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2013
• Employees: 385
• Stock Exchange: NASDAQ
• Ticker Symbol: KPTI

Financial Performance

In 2022, KPTI's revenue was $157.07 million, a decrease of -25.14% compared to the previous year's $209.82 million. Losses were -$165.29 million, 33.2% more than in 2021.

Analyst Forecast

According to 8 analysts, the average rating for KPTI stock is "Buy." The 12-month stock price forecast is $8.25, which is an increase of 265.04% from the latest price.

Price Target

$8.25

(265.04% upside)

Analyst Consensus: Buy